SRAX Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor SRAX te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Software winstgroei	16.9%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat SRAX onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:SRAX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2022	28	-32	-13	-12	N/A
9/30/2022	28	-22	-14	-13	N/A
6/30/2022	30	-21	-19	-18	N/A
3/31/2022	29	-3	-24	-23	N/A
12/31/2021	27	-10	-24	-23	N/A
9/30/2021	21	-6	-23	-22	N/A
6/30/2021	17	-4	-22	-21	N/A
3/31/2021	11	-11	-17	-17	N/A
12/31/2020	6	-10	-14	-13	N/A
9/30/2020	5	-19	-14	-13	N/A
6/30/2020	4	-11	-13	-12	N/A
3/31/2020	3	-14	-16	-15	N/A
12/31/2019	4	-17	-17	-15	N/A
9/30/2019	4	-21	-19	-17	N/A
6/30/2019	5	-1	-23	-22	N/A
3/31/2019	8	3	-17	-16	N/A
12/31/2018	10	9	-15	-14	N/A
9/30/2018	15	10	-12	-11	N/A
6/30/2018	19	-14	-4	-3	N/A
3/31/2018	20	-11	-5	-4	N/A
12/31/2017	23	-13	-5	-4	N/A
9/30/2017	28	-8	-5	-4	N/A
6/30/2017	32	-7	-4	-4	N/A
3/31/2017	36	-4	-2	-2	N/A
12/31/2016	36	-4	-1	-1	N/A
9/30/2016	32	-3	N/A	3	N/A
6/30/2016	30	-2	N/A	0	N/A
3/31/2016	32	-3	N/A	1	N/A
12/31/2015	30	-3	N/A	1	N/A
9/30/2015	26	-4	N/A	-1	N/A
6/30/2015	19	-4	N/A	-1	N/A
3/31/2015	9	-6	N/A	-3	N/A
12/31/2014	5	-4	N/A	-2	N/A
9/30/2014	3	-3	N/A	-2	N/A
6/30/2014	4	-3	N/A	-2	N/A
3/31/2014	4	-2	N/A	-1	N/A
12/31/2013	3	-2	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van SRAX boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van SRAX naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van SRAX naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van SRAX naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van SRAX naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SRAX naar verwachting over 3 jaar hoog zal zijn

SRAX Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast breakeven date pushed back to 2023

Price target increased to US$10.50

Price target increased to US$10.50

SRAX, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

SRAX, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Consensus forecasts updated

Recent updates

DNA Holdings LLC entered into a definitive merger agreement to acquire remaining 65% stake in SRAX, Inc. (OTCPK:SRAX).

SRAX, Inc. announced that it has received $0.075 million in funding

SRAX, Inc. announced that it has received $0.075 million in funding

SRAX, Inc. Announces Resignation of Board Members

Alan Urban Resigns as the Chief Financial Officer of SRAX, Inc

New major risk - Market cap size

First quarter 2022 earnings released: EPS: US$0.14 (vs US$0.57 loss in 1Q 2021)

Forecast breakeven date pushed back to 2023

SRAX, Inc., Annual General Meeting, Dec 31, 2022

Price target increased to US$10.50

SRAX, Inc. Launches the Sequire Investor Community Platform

SRAX Announces Receipt of Nasdaq Listing Determination

SRAX gets Nasdaq delisting notice, plans to appeal decision

Full year 2021 earnings released: US$0.41 loss per share (vs US$0.69 loss in FY 2020)

SRAX, Inc. Announces the Arcimoto Sweepstakes

SRAX Announces Receipt of Anticipated Nasdaq Notice of Additional Delinquency

Srax receives Nasdaq notice of additional delinquency

Is There An Opportunity With SRAX, Inc.'s (NASDAQ:SRAX) 50% Undervaluation?

Price target increased to US$10.50

SRAX announces $9.5M revolving credit facility

SRAX, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

SRAX, Inc. announced delayed 10-Q filing

SRAX, Inc. Receives Non-Compliance Notice from Nasdaq

SRAX, Inc. announced delayed annual 10-K filing

SRAX, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Is SRAX (NASDAQ:SRAX) A Risky Investment?

SRAX Offers Value Here

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$0.38 loss in 2Q 2020)

Does SRAX (NASDAQ:SRAX) Have A Healthy Balance Sheet?

SRAX Is Booming, Except The Share Price

Consensus forecasts updated

SRAX, Inc. (NasdaqCM:SRAX) announces an Equity Buyback for $10 million worth of its shares.

Price target increased to US$9.75

SRAX Releases the 1x1 Meeting Feature on the Sequire Virtual Events Platform

SRAX Has Plenty Of Room To Run

SRAX, Inc. announced delayed 10-Q filing

SRAX, Inc. Provides Revenue Guidance for the Second Quarter of Fiscal 2021

Full year 2020 earnings released: US$0.92 loss per share (vs US$1.36 loss in FY 2019)

SRAX, Inc. Provides Revenue Guidance for the Second Quarter Of Fiscal Year 2021

SRAX, Inc. Releases the Shelf Registration Feature on the Sequire Platform

Brock Pierce Joins SRAX Board of Directors

SRAX trades high on Sequire platform reporting 3M retail investors

New 90-day high: US$3.95

Does SRAX (NASDAQ:SRAX) Have A Healthy Balance Sheet?

New 90-day high: US$3.12

Analysts update estimates

SRAX, Inc., Annual General Meeting, Dec 31, 2020

Third quarter 2020 earnings released: US$0.45 loss per share

SRAX EPS misses by $0.14, beats on revenue

An undisclosed buyer acquired the remaining stake in the MD Asset of SRAX, Inc. (NasdaqCM:SRAX) for $8 million.

New 90-day low: US$2.34

SRAX, Inc. Announces Resignation of Kristoffer Nelson as Chief Operating Officer and as a Member of the Board, Effective October 16, 2020

SRAX, Inc. announced that it has received $14 million in funding from Serra Ventures, LLC

SRAX, Inc. (NasdaqCM:SRAX) completed the acquisition of LD Micro, Inc.

Analysts increase revenue estimates to US$5.72m

Analysts update estimates

New 90-day high - US$2.80

SRAX, Inc. announced that it has received $13 million in funding

SRAX, Inc.(NasdaqCM:SRAX) dropped from Russell Microcap Growth Index

SRAX, Inc. announced that it has received $11.8 million in funding

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven